Literature DB >> 11182038

Prevalence of silent prostatic adenocarcinoma in 165 patients undergone cystoprostatectomy: a retrospective study.

L Cindolo1, G Benincasa, R Autorino, S Domizio, G De Rosa, G Testa, M D'Armiento, V Altieri.   

Abstract

The reported prevalence of prostatic adenocarcinoma (PCa) in adults represents only the <tip of the iceberg>. The present retrospective study was carried out to estimate the prevalence of the silent PCa in 165 subjects (median age: 69 years; range: 40-82) undergone radical cystoprostatectomy for bladder cancer. To this aim, 38 subjects had routinely prostatic sampling by histology (group A), whereas 127 had systematic pathological sampling of the gland (group B). Silent PCa was diagnosed in 17 subjects (9.7%): 1 subject was in the group A (0.7%) and 16 were in the group B (9%). The data suggest that systematic examination of the prostatic specimens should be performed in order to approach the real prevalence of silent PCa in adult population.

Entities:  

Mesh:

Year:  2001        PMID: 11182038

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

1.  Preoperative findings, pathological stage PSA recurrence in men with prostate cancer incidentally detected at radical cystectomy: our experience in 242 cases.

Authors:  Pietro Pepe; Filippo Fraggetta; Antonio Galia; Paolo Panella; Michele Pennisi; Maurizio Colecchia; Francesco Aragona
Journal:  Int Urol Nephrol       Date:  2014-02-01       Impact factor: 2.370

2.  Characterization of prostate cancer incidentally detected in radical cystoprostatectomy specimens from Japanese men with bladder cancer.

Authors:  Toshifumi Kurahashi; Hideaki Miyake; Junya Furukawa; Masafumi Kumano; Atsushi Takenaka; Masato Fujisawa
Journal:  Int Urol Nephrol       Date:  2009-05-16       Impact factor: 2.370

3.  Clinicopathologic features of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens.

Authors:  Berna Aytac; Hakan Vuruskan
Journal:  World J Surg Oncol       Date:  2011-07-20       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.